$AQST

AQST Shareholders Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) for alleged violations of federal securities laws. The lawsuit claims Aquestive made false and misleading statements about the approval timeline for its Anaphylm NDA, failing to disclose significant human factors risks impacting regulatory approval. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit and have until May 4, 2026, to request to be appointed as lead plaintiff.

Original reporting
Published Apr 30, 2026, 3:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 30, 2026, 7:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AQST Shareholders Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! — source image
Decision brief

The 30-second read

$AQSTBearishHigh
01

Why it matters

The lawsuit's allegations could lead to stock price volatility, increased scrutiny, and potential delays or setbacks in product approval processes.

02

Market read

The legal action poses a material risk to AQST's stock performance and investor confidence, with potential ripple effects in the biotech sector.

03

What to watch

Potential positive developments in drug approval processes or settlement negotiations that could mitigate legal risks.

Timing: Immediate, as the lawsuit is recent and has a deadline for investors to join (May 4, 2026).

Background

Aquestive Therapeutics is facing a class action lawsuit alleging false and misleading statements regarding its NDA approval timeline, with significant legal and regulatory implications.

Company-level read

Ticker impact

$AQSTBearishHigh confidence
Context

High relevance due to legal action and potential impact on stock price.

Expected impact

Moderate to significant decline in short-term stock price, possibly 10-15% if legal proceedings intensify.

Evidence & confidence

Legal actions and allegations of securities law violations typically lead to negative investor sentiment and stock price declines, especially when the news is recent and involves material disclosures.

Market effects

Potential negative impact on the life sciences sector, especially biotech firms with similar regulatory and legal risks.

Limited regional impact; primarily affects US-based biotech stocks.

Low; specific to US securities and legal environment.

Counterpoint

Legal action may be a temporary setback; if AQST can demonstrate compliance and resolve issues, the stock could recover.

Key entities

  • Bronstein, Gewirtz & Grossman, LLC

    Law firm representing shareholders in the class action lawsuit.

  • Aquestive Therapeutics, Inc.

    The subject of the lawsuit, involved in drug development and regulatory approval.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.